PL2059246T3 - Kompozycje terapeutyczne zawierające swoistego antagonistę receptora endoteliny i inhibitor pde5 - Google Patents

Kompozycje terapeutyczne zawierające swoistego antagonistę receptora endoteliny i inhibitor pde5

Info

Publication number
PL2059246T3
PL2059246T3 PL07826167T PL07826167T PL2059246T3 PL 2059246 T3 PL2059246 T3 PL 2059246T3 PL 07826167 T PL07826167 T PL 07826167T PL 07826167 T PL07826167 T PL 07826167T PL 2059246 T3 PL2059246 T3 PL 2059246T3
Authority
PL
Poland
Prior art keywords
receptor antagonist
therapeutic compositions
endothelin receptor
pde5 inhibitor
specific endothelin
Prior art date
Application number
PL07826167T
Other languages
English (en)
Inventor
Martine Clozel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38954615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2059246(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of PL2059246T3 publication Critical patent/PL2059246T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07826167T 2006-08-29 2007-08-28 Kompozycje terapeutyczne zawierające swoistego antagonistę receptora endoteliny i inhibitor pde5 PL2059246T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IB2006052999 2006-08-29
IB2006053857 2006-10-19
PCT/IB2007/053448 WO2008026156A2 (en) 2006-08-29 2007-08-28 Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
EP07826167.4A EP2059246B1 (en) 2006-08-29 2007-08-28 Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor

Publications (1)

Publication Number Publication Date
PL2059246T3 true PL2059246T3 (pl) 2014-03-31

Family

ID=38954615

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07826167T PL2059246T3 (pl) 2006-08-29 2007-08-28 Kompozycje terapeutyczne zawierające swoistego antagonistę receptora endoteliny i inhibitor pde5

Country Status (27)

Country Link
US (8) US8268847B2 (pl)
EP (1) EP2059246B1 (pl)
JP (1) JP5208113B2 (pl)
KR (1) KR101473022B1 (pl)
CN (1) CN101511365B (pl)
AR (1) AR062501A1 (pl)
AU (1) AU2007290099B2 (pl)
BR (1) BRPI0715698B8 (pl)
CA (1) CA2659770C (pl)
CL (1) CL2007002494A1 (pl)
CY (1) CY1114735T1 (pl)
DK (1) DK2059246T3 (pl)
ES (1) ES2438792T3 (pl)
HK (1) HK1133597A1 (pl)
HR (1) HRP20131233T1 (pl)
IL (1) IL197235A (pl)
MA (1) MA30704B1 (pl)
MX (1) MX2009002057A (pl)
MY (1) MY154591A (pl)
NO (1) NO342554B1 (pl)
NZ (1) NZ575702A (pl)
PL (1) PL2059246T3 (pl)
PT (1) PT2059246E (pl)
RU (1) RU2462249C2 (pl)
SI (1) SI2059246T1 (pl)
TW (1) TWI388556B (pl)
WO (1) WO2008026156A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080233188A1 (en) 2005-09-12 2008-09-25 Actelion Pharmaceuticals Ltd. Stable Pharmaceutical Compositions Comprising a Pyrimidine - Sulfamide
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
ES2446303T3 (es) * 2008-02-20 2014-03-07 Actelion Pharmaceuticals Ltd. Combinación que comprende paclitaxel para el tratamiento del cáncer de ovarios
PL3300729T3 (pl) 2008-08-13 2020-04-30 Actelion Pharmaceuticals Ltd Kompozycje terapeutyczne zawierające macitentan
TWI462739B (zh) * 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN102949395A (zh) * 2011-09-22 2013-03-06 荆志成 盐酸伐地那非片在制备治疗肺动脉高压药物中的应用
CN102839165B (zh) * 2012-09-26 2014-12-10 金普诺安生物科技（苏州）有限公司 基因突变型重组蛋白酶k及其工业化生产方法
WO2014198178A1 (zh) * 2013-06-14 2014-12-18 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
KR20190030805A (ko) 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
MA54522A (fr) 2018-12-21 2022-03-23 Actelion Pharmaceuticals Ltd Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801584A1 (de) 1978-01-14 1979-07-19 Bayer Ag Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5589006A (en) * 1993-11-30 1996-12-31 Canon Kabushiki Kaisha Solar battery module and passive solar system using same
IL111959A (en) 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
WO1996016963A1 (de) 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
TW313568B (pl) 1994-12-20 1997-08-21 Hoffmann La Roche
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
RU2172735C2 (ru) 1995-12-20 2001-08-27 Яманоути Фармасьютикал Ко., Лтд. Арилэтенсульфонамидные производные и фармацевтическая композиция
GB2346877B (en) 1997-11-12 2001-12-05 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
ATE380180T1 (de) 1999-09-03 2007-12-15 Actelion Pharmaceuticals Ltd Bis-sulfonamiden
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
HUP0204168A2 (hu) 1999-12-22 2003-04-28 Actelion Pharmaceuticals Ltd. Butin-diol-származékok, ilyeneket tartalmazó gyógyszerkészítmény és előállítása
AU2001263850A1 (en) 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
WO2001081338A1 (en) 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
EP1345920B1 (en) 2000-12-18 2006-04-12 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7094081B1 (en) 2005-03-24 2006-08-22 Delphi Technologies, Inc. Electrical connector assembly
US20080233188A1 (en) 2005-09-12 2008-09-25 Actelion Pharmaceuticals Ltd. Stable Pharmaceutical Compositions Comprising a Pyrimidine - Sulfamide
RU2435585C2 (ru) 2006-04-13 2011-12-10 Актелион Фармасьютиклз Лтд Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких

Also Published As

Publication number Publication date
US20130005734A1 (en) 2013-01-03
US20180147205A1 (en) 2018-05-31
AU2007290099A1 (en) 2008-03-06
KR101473022B1 (ko) 2014-12-15
US20200352944A1 (en) 2020-11-12
US20200038401A1 (en) 2020-02-06
HRP20131233T1 (hr) 2014-01-31
CN101511365A (zh) 2009-08-19
IL197235A0 (en) 2009-12-24
MX2009002057A (es) 2009-03-06
BRPI0715698A2 (pt) 2013-08-06
BRPI0715698B1 (pt) 2020-01-21
RU2462249C2 (ru) 2012-09-27
MA30704B1 (fr) 2009-09-01
HK1133597A1 (en) 2010-04-01
NZ575702A (en) 2011-11-25
EP2059246A2 (en) 2009-05-20
CY1114735T1 (el) 2017-01-25
DK2059246T3 (da) 2013-12-02
BRPI0715698B8 (pt) 2021-05-25
US20140148460A1 (en) 2014-05-29
CN101511365B (zh) 2011-08-17
SI2059246T1 (sl) 2014-01-31
TWI388556B (zh) 2013-03-11
EP2059246B1 (en) 2013-10-16
ES2438792T3 (es) 2014-01-20
IL197235A (en) 2014-04-30
AU2007290099B2 (en) 2013-01-31
US20210177849A1 (en) 2021-06-17
US20190083494A1 (en) 2019-03-21
WO2008026156A3 (en) 2008-10-16
CL2007002494A1 (es) 2008-04-04
CA2659770C (en) 2014-11-18
KR20090057009A (ko) 2009-06-03
US8268847B2 (en) 2012-09-18
US20130210830A9 (en) 2013-08-15
RU2009111378A (ru) 2010-10-10
WO2008026156A2 (en) 2008-03-06
MY154591A (en) 2015-06-30
PT2059246E (pt) 2013-12-16
US20090318459A1 (en) 2009-12-24
TW200823198A (en) 2008-06-01
NO342554B1 (no) 2018-06-11
JP2010502588A (ja) 2010-01-28
AR062501A1 (es) 2008-11-12
NO20091254L (no) 2009-03-26
JP5208113B2 (ja) 2013-06-12
CA2659770A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
HK1133597A1 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
HUS2100003I1 (hu) Angiotenzin receptor antagonista és NEP inhibitor gyógyszerészeti kombinációja
EP2050749A4 (en) PYRIMIDIN DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF
EP2035005A4 (en) THERAPY BASED ON CYTOKINE INHIBITORS
GB0625659D0 (en) Therapeutic compounds and their use
GB2436082B (en) Tactile tiling
HK1208000A1 (en) Thioninium compounds and their use
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
TWI367112B (en) Immediate-release tablet formulations of a thrombin receptor antagonist
IL198780A0 (en) Pharmaceutical formulation comprising neurokinin antagonist
GB0611115D0 (en) Compounds and their use
EP2029132A4 (en) ANTIHISTAMINE COMPOSITIONS AND THEIR USE
GB0614365D0 (en) Pharmaceutical compositions and their use
ZA200903523B (en) Poly-TLR antagonist
EP2097446A4 (en) RESISTANT ANTAGONISTS AND ITS USE
EP2067480A4 (en) MUSCLIN RECEPTOR AND USE THEREOF
GB0619611D0 (en) Compounds and their use
ZA200902164B (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB0625633D0 (en) Therapeutic compounds and their use
GB0608846D0 (en) Compounds and their use
GB0603374D0 (en) Compounds and their use
GB0603378D0 (en) Compounds and their use
GB0616577D0 (en) Compounds and their use
GB0610888D0 (en) Compounds and their use